Standard BioTools Inc (LAB) USD0.001

Sell:$1.03Buy:$1.44$0.07 (5.69%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.03
Buy:$1.44
Change:$0.07 (5.69%)
Market closed | Prices delayed by at least 15 minutes
Sell:$1.03
Buy:$1.44
Change:$0.07 (5.69%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.

Key people

Michael Egholm
President, Chief Executive Officer, Director
Hanjoon Alex Kim
Chief Financial Officer
Tom Carey
Independent Chairman of the Board
Eli D. Casdin
Independent Director
Troy Cox
Independent Director
Fenel M. Eloi
Independent Director
Kathy Hibbs
Independent Director
Click to see more

Key facts

  • EPIC
    LAB
  • Location
    United States
  • Sector
    Technology
  • Industry
    Scientific & Technical Instr.
  • ISIN
    US34385P1084
  • Market cap
    $469.94m
  • Employees
    818
  • Shares in issue
    397.57m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.